We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Membrane-binding Protein Regulates Cell Motility by Sensing Membrane Tension

By LabMedica International staff writers
Posted on 17 May 2015
A team of Japanese cell biologists has found that the interaction between the degree of plasma membrane tension and a plasma membrane-bending protein regulates cell motility, and that this interaction is disrupted in metastasizing cancer cells.

Investigators at Kobe University (Japan) worked with a cultured tumor cell line in studies that succeeding in identifying the link between the membrane-bending protein FBP17 (formin-binding protein-17) and the degree of tension found at a cell's leading edge formation.

The investigators reported in the May 4, 2015, online edition of the journal Nature Cell Biology that FBP17, an activator of WASP (Wiskott–Aldrich Syndrome protein)/N-WASP-dependent actin nucleation, was a plasma membrane tension sensor involved in leading edge formation. More...
In migrating cells, FBP17 localized to short membrane invaginations at the leading edge, while diminishing from the cell rear in response to plasma membrane tension increase. Conversely, following reduced plasma membrane tension, FBP17 dots randomly distributed throughout the cell, correlating with loss of polarized actin assembly on plasma membrane tension reduction.

In vitro experiments showed that FBP17 membrane-bending activity depended on liposomal membrane tension. Thus, FBP17 was the local activator of actin polymerization that was inhibited by plasma membrane tension in the feedback loop that regulated cell migration. The disruption of cell motility-regulating mechanisms has been cited as a key factor in cancer cell metastasis.

Senior author Dr. Toshiki Itoh, professor of biomedical science at Kobe University, said, "We are promoting research from a less studied perspective to identify new approaches to cancer treatment."

Related Links:

Kobe University



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.